+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are conducting a Phase 3 global, multicenter, 52-week open-label extension study to assess the long-term safety and tolerability of KarXT in people with psychosis associated with Alzheimers Disease. This study includes participants who have completed prior related studies, allowing continued evaluation of this treatment over an extended period. Participants receive KarXT capsules in various doses ranging from 202 mg to 66.76.67 mg three times daily. This extension study follows completion of earlier trials and continues treatment for up to 52 weeks to monitor long-term effects and safety. During the study, participants are monitored for treatment-emergent adverse events from the initial dose through 14 days after the last dose, totaling up to 54 weeks. Researchers track serious adverse events and withdrawals due to adverse events. The involvement lasts approximately one year, focusing on safety and tolerability assessments.

Age: 55Years - 90YearsAll GendersPhase 3
432 locations
R

Actively Recruiting

Researchers are evaluating the efficacy of ALTO-300 compared to placebo as an add-on treatment to antidepressants in adults with moderate to severe major depressive disorder MDD. This Phase 2 study aims to understand how patient characteristics might influence the effectiveness of ALTO-300 in improving depression symptoms. The study uses a randomized, double-blind, placebo-controlled design with a subsequent open-label extension phase. Participants will be assigned to receive either ALTO-300 capsules or matching placebo capsules once daily in the evening for 42 days during the double-blind period. Those who qualify for the open-label phase will continue taking ALTO-300 daily for up to an additional 8 weeks. Throughout both phases, the study monitors treatment effects and safety. During the trial, participants will undergo assessments to measure changes in depression symptoms using the Montgomery-sberg Depression Rating Scale MADRS over six weeks. Safety evaluations include monitoring adverse events, heart rate, weight, blood pressure, and suicidality through specialized questionnaires. The total study duration includes the double-blind phase and the open-label extension, with ongoing safety and efficacy monitoring until study completion.

Age: 18Years - 70YearsAll GendersPhase 2
75 locations